Description of Invention:
The invention described herein are peptides and polypeptides derived from the HA, NA, PB2, PB1, PA, M1, M2, NP, NS1, and NS2 proteins of influenza virus that elicit immunogenic responses; particularly neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7. Materials in the form of immunogenic compositions including these peptides and polypeptides can also be in-licensed along with the patent rights. Pharmaceutical compositions including these peptides and polypeptides with or without adjuvants are within the scope of the invention. The inventors are currently investigating the vaccine potential of specific peptides and polypeptides.
Applications:
Vaccines against influenza virus infection;
Diagnostics for the detection of influenza virus infection; and
Generation of influenza virus specific antibodies.
Advantages:
Peptides can be expressed in a number of different expression systems; and
Peptides were identified based on the specificity of antibodies derived from human and avian influenza virus infected individuals.
Development Status: In vitro data can be provided upon request.
Market:
Preventative or treatment for influenza virus infection; and
Diagnostic for influenza virus infection.
Inventors: Hana Golding and Surender Khurana (FDA)
Patent Status:
DHHS Reference No. E-236-2007/3 --
International Patent Application PCT/US2008/067001 filed 13 Jun 2008
Relevant Publication:
Pandemic Influenza preparedness: New molecular tools for evaluation of influenza vaccines and identification of serological epitopes for avian influenza diagnostic assays at “Options for the Control of Influenza VI” June 17-23, 2007, Toronto, Canada. (oral presentation)
Pandemic Influenza preparedness: Identification of serological epitopes for use in development of broadly cross-reactive influenza vaccines at “National Foundation for Infectious Diseases - 11th Annual Conference on Vaccine Research”, Baltimore: May 5-7, 2008. (oral presentation)
Analysis of antibody repertoires in H5N1 infected and vaccinated individuals using influenza whole genome phage display at “Immunobiology and Pathogenesis of Influenza Infection”, Atlanta: June 1-3, 2008. (poster presentation)
Licensing Status: Available for exclusive or non-exclusive licensing.
Collaborative Research Opportunity:
The FDA, Center for Biologics Evaluation and Research (CBER), Division of Viral Products, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these peptides as vaccine candidates or diagnostics. Please contact Alice Welch at alice.welch@fda.hhs.gov or 301-827-0359 for more information.
For Additional Information Please Contact: Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-5018
Email: changke@mail.nih.gov
Fax: 301/402-0220
